The post The FDA Is Trying To Make Corporate Free Speech Situational appeared on BitcoinEthereumNews.com. BENSENVILLE, ILLINOIS – SEPTEMBER 10: Flanked by U.S. Attorney General Pam Bondi (rear), and FDA Commissioner Marty Makary (R), Secretary of Health and Human Services Robert F. Kennedy Jr. speaks to the press outside Midwest Distribution after it was raided by federal agents on September 10, 2025 in Bensenville, Illinois. According to the company, various e-liquids were seized in the raid. (Photo by Scott Olson/Getty Images) Getty Images While running for President in 2008, Barack Obama famously chanted “Yes we can.” Love or hate his political views, Obama’s politics were quite effective. He was asking voters to think big, to envision a much better future. Advertisers no doubt approved. That’s because ads routinely evoke things not as they are, but as they could be. Gyms and exercise equipment companies don’t promote their locations and equipment with flabby, lumbering people, rather their ads show fit, upright, energetic individuals. A look ahead. Restaurants do the same with ads showing happy people enjoying impressively put together plates of food. Conversely, ads meant to convince smokers to quit have not infrequently shown the worst of the worst future downsides of the habit. The nature of advertising comes to mind as FDA commissioner Marty Makary puzzlingly brags that “The Trump Administration Is Taking On Big Pharma” in the New York Times. Makary laments pharmaceutical ads that “are filled with dancing patients, glowing smiles and catch jingles that drown out the fine print.” Not explained is whether Makary would be happier if drug companies placed ads with immobile patients, frowns, and funereal music. Seriously, what does he expect? Does he want drug companies to commit billions to drug development to accompany their achievements with imagery defined by misery? Has Makary stopped to contemplate the myriad shareholders lawsuits drugmakers would face if, upon risking staggering sums meant… The post The FDA Is Trying To Make Corporate Free Speech Situational appeared on BitcoinEthereumNews.com. BENSENVILLE, ILLINOIS – SEPTEMBER 10: Flanked by U.S. Attorney General Pam Bondi (rear), and FDA Commissioner Marty Makary (R), Secretary of Health and Human Services Robert F. Kennedy Jr. speaks to the press outside Midwest Distribution after it was raided by federal agents on September 10, 2025 in Bensenville, Illinois. According to the company, various e-liquids were seized in the raid. (Photo by Scott Olson/Getty Images) Getty Images While running for President in 2008, Barack Obama famously chanted “Yes we can.” Love or hate his political views, Obama’s politics were quite effective. He was asking voters to think big, to envision a much better future. Advertisers no doubt approved. That’s because ads routinely evoke things not as they are, but as they could be. Gyms and exercise equipment companies don’t promote their locations and equipment with flabby, lumbering people, rather their ads show fit, upright, energetic individuals. A look ahead. Restaurants do the same with ads showing happy people enjoying impressively put together plates of food. Conversely, ads meant to convince smokers to quit have not infrequently shown the worst of the worst future downsides of the habit. The nature of advertising comes to mind as FDA commissioner Marty Makary puzzlingly brags that “The Trump Administration Is Taking On Big Pharma” in the New York Times. Makary laments pharmaceutical ads that “are filled with dancing patients, glowing smiles and catch jingles that drown out the fine print.” Not explained is whether Makary would be happier if drug companies placed ads with immobile patients, frowns, and funereal music. Seriously, what does he expect? Does he want drug companies to commit billions to drug development to accompany their achievements with imagery defined by misery? Has Makary stopped to contemplate the myriad shareholders lawsuits drugmakers would face if, upon risking staggering sums meant…

The FDA Is Trying To Make Corporate Free Speech Situational

For feedback or concerns regarding this content, please contact us at [email protected]

BENSENVILLE, ILLINOIS – SEPTEMBER 10: Flanked by U.S. Attorney General Pam Bondi (rear), and FDA Commissioner Marty Makary (R), Secretary of Health and Human Services Robert F. Kennedy Jr. speaks to the press outside Midwest Distribution after it was raided by federal agents on September 10, 2025 in Bensenville, Illinois. According to the company, various e-liquids were seized in the raid. (Photo by Scott Olson/Getty Images)

Getty Images

While running for President in 2008, Barack Obama famously chanted “Yes we can.” Love or hate his political views, Obama’s politics were quite effective. He was asking voters to think big, to envision a much better future.

Advertisers no doubt approved. That’s because ads routinely evoke things not as they are, but as they could be. Gyms and exercise equipment companies don’t promote their locations and equipment with flabby, lumbering people, rather their ads show fit, upright, energetic individuals. A look ahead. Restaurants do the same with ads showing happy people enjoying impressively put together plates of food. Conversely, ads meant to convince smokers to quit have not infrequently shown the worst of the worst future downsides of the habit.

The nature of advertising comes to mind as FDA commissioner Marty Makary puzzlingly brags that “The Trump Administration Is Taking On Big Pharma” in the New York Times. Makary laments pharmaceutical ads that “are filled with dancing patients, glowing smiles and catch jingles that drown out the fine print.” Not explained is whether Makary would be happier if drug companies placed ads with immobile patients, frowns, and funereal music.

Seriously, what does he expect? Does he want drug companies to commit billions to drug development to accompany their achievements with imagery defined by misery? Has Makary stopped to contemplate the myriad shareholders lawsuits drugmakers would face if, upon risking staggering sums meant to create a healthier future, they made sure to downplay or outright deny their achievements?

Makary pats his FDA and Trump administration on the back for acting to “rein in misleading pharmaceutical ads,” but it’s the equivalent of the Trump administration demanding that pharmaceutical companies demean their capabilities. How could the allegedly pro-business Trump administration make such a demand, one that no other politician or business would ever be expected to abide?

To which Makary and his defenders might reply that with pharmaceutical drugs, the rules should be different. Since health and health outcomes are on the line, sometimes of the life and death variety, pharmaceutical companies must follow a different set of rules. Except that pharmaceutical companies already do. And Makary knows this truth well.

As evidenced by the years of work and billions spent just to attain drug approval, pharmaceutical companies go to enormous lengths to get their innovations into the marketplace. Their drugs are FDA approved. Which is the point, or should be.

In seeking greater policing of drug advertising, Makary is adding another layer to the already substantial oversight provided by the FDA, oversight that has yet more layers. While pharmaceutical companies can advertise their FDA approved drugs, would-be patients can still only attain them insofar as they’re prescribed by a doctor. Which of course answers Makary’s odd critique that drugmakers are targeting potential users with “misleading ads.” Really? How?

Lest Makary forget, the ads are yet again for FDA approved drugs that are once again only accessible with a doctor-signed prescription. Which raises a basic question: if the FDA is doing its job in the approval process, and doctors are doing their jobs, why the limits on the free speech rights of pharmaceutical companies to advertise the health possibilities that come with their innovations? Why indeed.

Absent a compelling answer from Makary, it’s difficult to find a compelling reason for the Trump administration to make free speech situational. Pharmaceutical companies prosper by improving our lives. Let them advertise their capacity to do just that.

Source: https://www.forbes.com/sites/johntamny/2025/09/17/the-fda-is-trying-to-make-corporate-free-speech-situational/

Market Opportunity
SynFutures Logo
SynFutures Price(F)
$0.005116
$0.005116$0.005116
+0.53%
USD
SynFutures (F) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

[Vantage Point] How Corporate Philippines is quietly war-gaming a supply shock

[Vantage Point] How Corporate Philippines is quietly war-gaming a supply shock

An empty gas station along Kalayaan Avenue in Quezon City is seen without customers because its fuel supply ran out on March 9, 2026, ahead of a new round of oil
Share
Rappler2026/03/31 12:00
Ondo Finance Launches USDY Yieldcoin on Stellar, Bringing Tokenized U.S. Treasuries to Users

Ondo Finance Launches USDY Yieldcoin on Stellar, Bringing Tokenized U.S. Treasuries to Users

Ondo Finance, a U.S.-based digital asset firm specializing in bringing traditional financial products on-chain through tokenization, is expanding its yieldcoin USDY to the Stellar network. This lates update marks a step forward in merging tokenized real-world assets with a global payments infrastructure, unlocking new opportunities for users worldwide. The announcement was made at the Stellar Meridian event in Copacabana, Rio de Janeiro, on September 17. USDY Joins the Stellar Ecosystem Ondo Finance, a recognized leader in tokenized real-world assets, announced the deployment of United States Dollar Yield (USDY) on Stellar, the payments-focused blockchain known for speed and low transaction costs. USDY is the most widely available “yieldcoin,” offering investors access to onchain assets backed by U.S. Treasuries. This launch allows Stellar’s global user base to tap into permissionless, yield-bearing assets tied to one of the safest financial instruments in the world. It also aligns with Stellar’s mission of driving fast, affordable cross-border payments. Combining Yield with Payments Infrastructure “Stablecoins unlocked global access to the U.S. dollar. With USDY, we’re taking the next step by bringing U.S. Treasuries onchain in a form that combines stability, liquidity, and yield,” said Ian De Bode, Chief Strategy Officer at Ondo Finance. “Fast, affordable cross-border payments are at the center of what Stellar was designed to do. The global reach of the Stellar ecosystem combined with a yield-bearing asset like USDY levels up what is possible onchain, allowing wallets and businesses to offer yield opportunities to their users,” said Denelle Dixon, CEO of the Stellar Development Foundation. Ondo claims by pairing USDY with Stellar’s infrastructure, new possibilities open up in treasury management, collateralization, and everyday financial applications. Unlocking Institutional and Retail Use Cases USDY currently manages over $650 million in total value locked (TVL) across nine blockchains and offers a 5.3% APY. By launching on Stellar, Ondo Finance extends these benefits to global retail and institutional users. The firm explains balances on Stellar can now become productive, supporting use cases such as onchain savings, institutional treasury strategies, cost-efficient collateral for DeFi protocols, and remittance flows that carry yield rather than remaining static. A Milestone for Tokenized Treasuries With the integration of USDY, Stellar users gain more than just access to stable-value assets—they gain access to institutional-grade yield. For investors outside the U.S., the launch represents a new way to combine the safety of Treasuries with the accessibility of blockchain technology. As tokenization accelerates globally, Ondo Finance’s decision to deploy USDY on Stellar reinforces the narrative that blockchain is not just about speculation, but about reimagining the global financial system through secure, yield-bearing digital assets
Share
CryptoNews2025/09/18 00:46
Midas Raises $50M for Instant Liquidity Layer in Tokenized RWAs

Midas Raises $50M for Instant Liquidity Layer in Tokenized RWAs

The post Midas Raises $50M for Instant Liquidity Layer in Tokenized RWAs appeared on BitcoinEthereumNews.com. Tokenization startup Midas’s Series A round was led
Share
BitcoinEthereumNews2026/03/31 12:06